| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $47,197,008 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R37CA248298 | Role of Sirt2 in T Cell Metabolism | 002 | 6 | NIH | 2/14/2025 | $322,194 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA295558 | Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II Inhibitor | 000 | 1 | NIH | 12/25/2024 | $607,634 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG076537 | Extracellular vesicle-based senotherapeutics for aging diabetic kidneydisease | 001 | 3 | NIH | 8/29/2025 | $46,318 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG076537 | Extracellular vesicle-based senotherapeutics for aging diabetic kidneydisease | 000 | 3 | NIH | 3/24/2025 | $521,046 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA288808 | Epigenetic Regulation of T Cell Metabolism and Immune Functions by Sirt6 | 000 | 1 | NIH | 12/18/2024 | $219,491 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R35NS137447 | Expanding insights into FTD disease mechanisms | 000 | 1 | NIH | 12/6/2024 | $1,138,538 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077771 | Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS | 001 | 3 | NIH | 8/11/2025 | $57,623 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077771 | Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS | 000 | 3 | NIH | 11/19/2024 | $648,262 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA296671 | ECT2 Isoform Switch in Pancreatic Cancer. | 000 | 1 | NIH | 11/21/2024 | $219,491 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U24CA277825 | The Data, Evaluation, and Coordination Center (DECC) for Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) | 002 | 5 | NIH | 8/14/2025 | $448,648 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01DK139604 | Protein Kinase D1 as a switch from acute to chronic pancreatitis | 000 | 2 | NIH | 4/15/2025 | $340,388 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA279916 | Deiminated molecules as markers for developing pancreatic cancer - A1 | 001 | 2 | NIH | 6/2/2025 | $21,949 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA279916 | Deiminated molecules as markers for developing pancreatic cancer - A1 | 000 | 2 | NIH | 11/15/2024 | $197,542 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HL169268 | Individualized medicine to predict and prevent chemotherapy-related heart failure | 000 | 3 | NIH | 7/24/2025 | $641,876 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 001 | 4 | NIH | 8/11/2025 | $239,814 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 000 | 4 | NIH | 12/6/2024 | $2,697,909 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HL164520 | Role of mitochondrial extracellular vesicles in CVB3 myocarditis by sex | 000 | 4 | NIH | 7/4/2025 | $721,646 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HL140411 | Distinct Pathways of VPF/VEGF Receptors | 000 | 6 | NIH | 7/23/2025 | $653,379 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG079859 | Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s disease | 001 | 3 | NIH | 7/24/2025 | $43,820 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG079859 | Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s disease | 000 | 3 | NIH | 1/28/2025 | $492,975 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01DK117910 | Mechanisms of Hereditary Pancreatitis | 002 | 6 | NIH | 4/15/2025 | $690,067 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG087165 | Elucidating the Pathomechanisms of APOE4 in Lewy Body Dementia | 001 | 2 | NIH | 6/10/2025 | $62,170 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG087165 | Elucidating the Pathomechanisms of APOE4 in Lewy Body Dementia | 000 | 2 | NIH | 3/14/2025 | $699,413 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS129671 | Tumor targeted drug delivery nanoplatform to overcome therapy resistance glioblastoma | 000 | 3 | NIH | 12/13/2024 | $556,541 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AG088076 | Standardizing and Harmonizing Behavioral and Social Science Research Factors in Alzheimer's Disease through Ontology-Based Approaches | 001 | 2 | NIH | 8/18/2025 | $752,353 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AG088076 | Standardizing and Harmonizing Behavioral and Social Science Research Factors in Alzheimer's Disease through Ontology-Based Approaches | 002 | 2 | NIH | 8/27/2025 | $399,830 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AG088076 | Standardizing and Harmonizing Behavioral and Social Science Research Factors in Alzheimer's Disease through Ontology-Based Approaches | 002 | 2 | NIH | 8/27/2025 | -$399,830 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG089380 | Bio-RaPID: Biomarkers and Rates of Progression In Dementia. | 001 | 2 | NIH | 6/30/2025 | $2,285,244 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 004 | 3 | NIH | 7/31/2025 | $747,550 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 002 | 3 | NIH | 3/25/2025 | $8,409,935 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 003 | 3 | NIH | 4/1/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R13CA290996 | Science of Community Outreach and Engagement (SoCOE) Conference | 000 | 2 | NIH | 7/10/2025 | $10,000 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG054199 | APOE and microglia-mediated progression in tau pathology in AD | 001 | 4 | NIH | 8/11/2025 | $721,020 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS123052 | C9orf72-mediated features transcriptomic signatures and translational studies for frontotemporal dementia and related disorders | 000 | 2 | NIH | 7/4/2025 | $788,248 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 001 | 2 | NIH | 6/23/2025 | $564 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 000 | 2 | NIH | 11/15/2024 | $49,174 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077656 | Accelerated Resolution Therapy for Early Maladaptive Grief: A Clinical Trial | 001 | 3 | NIH | 6/17/2025 | $52,690 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077656 | Accelerated Resolution Therapy for Early Maladaptive Grief: A Clinical Trial | 000 | 3 | NIH | 3/6/2025 | $592,775 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS132330 | Investigating the role of TMEM106b genetics and pathology in Alzheimer’s disease, LATE and FTLD | 000 | 3 | NIH | 8/26/2025 | $1,060,236 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS137907 | Targeting Signaling Between Glioblastoma and the Subventricular Zone Niche | 000 | 2 | NIH | 8/5/2025 | $434,922 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA276313 | A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer | 000 | 3 | NIH | 6/26/2025 | $639,109 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA266113 | Disease Progression Modeling of Bladder Cancer | 000 | 3 | NIH | 7/10/2025 | $497,514 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG084236 | ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System | 003 | 3 | NIH | 7/14/2025 | $973,545 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS121075 | Metabolic interactions between tumor cells and the immune system in GBM: A potential Achilles heel of GBM for novel therapeutics | 001 | 4 | NIH | 7/3/2025 | $366,265 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG078615 | Discovery of apoE4 modulators for Alzheimer’s disease therapy | 001 | 4 | NIH | 6/18/2025 | $33,995 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG078615 | Discovery of apoE4 modulators for Alzheimer’s disease therapy | 000 | 4 | NIH | 4/9/2025 | $382,444 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS121125 | Frontotemporal dementia and related disorders: transcriptomic profiling, biomarker discovery, and mechanistic insight | 000 | 5 | NIH | 7/17/2025 | $780,935 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01CA274970 | A Multi-level Approach to Connecting Individuals to Cancer Clinical Research | 001 | 5 | NIH | 8/18/2025 | $470,401 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K23DK131338 | Approaches and Outcomes of Shared Decision-making and Patient Centered Care Delivery in Barrett's Esophagus | 003 | 4 | NIH | 5/14/2025 | $199,171 |
|
